- Home
- AIRJ vs AVIR Comparison
AIRJ vs AVIR Comparison
Compare AIRJ & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRJ
- AVIR
- Stock Information
- Founded
- AIRJ 2018
- AVIR 2012
- Country
- AIRJ United States
- AVIR United States
- Employees
- AIRJ N/A
- AVIR N/A
- Industry
- AIRJ
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- AIRJ
- AVIR Health Care
- Exchange
- AIRJ NYSE
- AVIR Nasdaq
- Market Cap
- AIRJ 256.6M
- AVIR 273.0M
- IPO Year
- AIRJ N/A
- AVIR 2020
- Fundamental
- Price
- AIRJ $4.73
- AVIR $3.72
- Analyst Decision
- AIRJ Strong Buy
- AVIR Hold
- Analyst Count
- AIRJ 1
- AVIR 1
- Target Price
- AIRJ $12.00
- AVIR $6.00
- AVG Volume (30 Days)
- AIRJ 301.0K
- AVIR 403.3K
- Earning Date
- AIRJ 08-22-2025
- AVIR 08-06-2025
- Dividend Yield
- AIRJ N/A
- AVIR N/A
- EPS Growth
- AIRJ N/A
- AVIR N/A
- EPS
- AIRJ 0.86
- AVIR N/A
- Revenue
- AIRJ N/A
- AVIR N/A
- Revenue This Year
- AIRJ N/A
- AVIR N/A
- Revenue Next Year
- AIRJ N/A
- AVIR N/A
- P/E Ratio
- AIRJ $5.64
- AVIR N/A
- Revenue Growth
- AIRJ N/A
- AVIR N/A
- 52 Week Low
- AIRJ $3.74
- AVIR $2.46
- 52 Week High
- AIRJ $11.75
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- AIRJ 52.68
- AVIR 70.64
- Support Level
- AIRJ $4.43
- AVIR $3.63
- Resistance Level
- AIRJ $5.63
- AVIR $3.78
- Average True Range (ATR)
- AIRJ 0.40
- AVIR 0.14
- MACD
- AIRJ 0.05
- AVIR 0.02
- Stochastic Oscillator
- AIRJ 41.10
- AVIR 80.65
About AIRJ MONTANA TECHNOLOGIES CORP
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).